Pooled Analysis of HCV Genotype 1 Resistance-Associated Substitutions in NS5A,NS3 and NS5B pre- and Post-Treatment with 12 Weeks of Daclatasvir,Asunaprevir and Beclabuvir

Abstract

Background

Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non-nucleoside NS5B inhibitor) is an approved regimen for hepatitis C virus (HCV) genotype (GT)-1 treatment in Japan. A comprehensive analysis of pre-treatment and treatment-emergent HCV resistance to this regimen ± ribavirin (RBV) was performed.

Methods

Data were pooled from five Phase 2/3 studies of DCV+ASV+BCV±RBV given for 12 weeks to GT-1a- or GT-1b-infected patients. The prevalence and impact of pre-treatment resistance-associated substitutions (RAS) in NS5A, NS3, and NS5B on sustained virological response (SVR) was assessed, as were emergent RAS and their post-treatment persistence.

Results

Baseline NS5A RAS (GT-1a: M28T, Q30H/L/R/S, L31M, Y93C/H; GT-1b: L31I/M, Y93C/H) were present in 5% (26/561) of GT-1a and 16% (85/537) of GT-1b sequences. SVR12 for GT-1b without RBV was 100% (82/82) with RAS and >99% (427/428) without RAS. For GT-1a, SVR12 without RAS was 97% (85/88) with RBV and 92% (410/447) without RBV; SVR12 with RAS was 100% (2/2) with RBV and 54% (13/24) without RBV. Baseline NS3 (at R155 or D168) and NS5B (at P495) RAS were rare (≤1%). Treatment-emergent NS5A RAS (mostly Q30E/H/K/R+Y93H/N) in GT-1a persisted 60 weeks post-treatment, while NS3 RAS (mostly R155K) and NS5B-P495L/S were no longer detected after 48 or 24 weeks, respectively.

Conclusions

DCV+ASV+BCV+RBV was highly efficacious in HCV GT-1 infection, including HCV GT-1b with NS5A RAS. The fitness of treatment-emergent RAS post-treatment was NS5A > NS3 > NS5B; NS3 and NS5B RAS were generally replaced by wild-type sequence within 48 weeks.

References

Smith

D.B.

, Bukh

, Kuiken

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource.

Hepatology 2014; 59: 318–327.

Martell

, Esteban

J.I.

, Quer

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

J Virol 1992; 66: 3225–3229.

Pawlotsky

J.M.

Hepatitis C virus genetic variability: pathogenic and clinical implications.

Clin Liver Dis 2003; 7: 45–66.

Gao

Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Curr Opin Virol 2013; 3: 514–520.

Sarrazin

, Lathouwers

, Peeters

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

Antiviral Res 2015; 116: 10–16.

Lemm

J.A.

, Liu

, Gentles

R.G.

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase.

Antimicrob Agents Chemother 2014; 58: 3485–3495.

Coffin

J.M.

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Science 1995; 267: 483–489.

Lok

A.S.

, Gardiner

D.F.

, Lawitz

Preliminary study of two antiviral agents for hepatitis C genotype 1.

N Engl J Med 2012; 366: 216–224.

Gao

, Nettles

R.E.

, Belema

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Nature 2010; 465: 96–100.

10.

McPhee

, Sheaffer

A.K.

, Friborg

Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032).

Antimicrob Agents Chemother 2012; 56: 5387–5396.

11.

Everson

G.T.

, Sims

K.D.

, Thuluvath

P.J.

Daclatasvir + asunaprevir + beclabuvir +/- ribavirin for chronic HCV genotype 1-infected treatment-naive patients.

Liver Int 2016; 36: 189–197.

12.

Poordad

, Sievert

, Mollison

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

JAMA 2015; 313: 1728–1735.

13.

Muir

A.J.

, Poordad

, Lalezari

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

JAMA 2015; 313: 1736–1744.

14.

Toyota

, Karino

, Suzuki

Daclatasvir/asunaprevir/ beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

J Gastroenterol 2017; 52: 385–395.

15.

Kao

J.H.

, Yu

M.L.

, Peng

C.Y.

Daclatasvir/asunaprevir/ beclabuvir (DCV-TRIO), all-oral, fixed-dose combination for patients with chronic HCV genotype 1.

J Gastroenterol Hepatol 2017; doi:10.1111/jgh.13796.

16.

Zhou

, Han

, Hartman-Neumann

Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.

J Antimicrob Chemother 2016; 71: 3495–3505.

17.

Zhou

, Hernandez

, Ueland

NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection.

J Infect Dis 2016; 213: 206–215.

18.

Hernandez

, Zhou

, Ueland

, Monikowski

, McPhee

Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.

J Clin Virol 2013; 57: 13–18.

19.

McPhee

, Suzuki

, Toyota

High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms.

Adv Ther 2015; 32: 637–649.

20.

Fridell

R.A.

, Qiu

, Wang

, Valera

, Gao

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

Antimicrob Agents Chemother 2010; 54: 3641–3650.

21.

McPhee

, Hernandez

, Yu

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.

Hepatology 2013; 58: 902–911.

22.

McPhee

, Hernandez

, Zhou

Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.

Antivir Ther 2014; 19: 479–490.

23.

Cuypers

, Li

, Neumann-Haefelin

Mapping the genomic diversity of HCV subtypes 1a and 1b: implications of structural and immunological constraints for vaccine and drug development.

Virus Evol 2016; 2: vew024.

24.

McPhee

, Friborg

, Levine

Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.

Antimicrob Agents Chemother 2012; 56: 3670–3681.

25.

Manns

, Pol

, Jacobson

I.M.

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, Phase 3, multicohort study.

Lancet 2014; 384: 1597–1605.

26.

Pelosi

L.A.

, Voss

, Liu

, Gao

, Lemm

J.A.

Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.

Antimicrob Agents Chemother 2012; 56: 5230–5239.

27.

Tomei

, Altamura

, Bartholomew

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

J Virol 2003; 77: 13225–13231.

28.

Liu

, Tuttle

, Gao

, Lemm

J.A.

Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.

Antimicrob Agents Chemother 2014; 58: 7416–7423.

29.

Hernandez

, Yu

, Huang

, Kirov

, Pant

, McPhee

Impact of pre-existing NS5A-L31 or -Y93H minor variants on response rates in patients infected with HCV genotype-1b treated with daclatasvir/asunaprevir.

Adv Ther 2016; 33: 1169–1179.

30.

Karino

, Toyota

, Ikeda

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

J Hepatol 2013; 58: 646–654.

31.

Hassanein

, Sims

K.D.

, Bennett

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

J Hepatol 2015; 62: 1204–1206.

32.

Sheaffer

A.K.

, Lee

M.S.

, Hernandez

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.

Antivir Ther 2011; 16: 705–718.

33.

Fridell

R.A.

, Wang

, Sun

J.H.

Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations.

Hepatology 2011; 54: 1924–1935.

34.

Pasquinelli

, McPhee

, Eley

Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Antimicrob Agents Chemother 2012; 56: 1838–1844.

35.

McPhee

, Hernandez

, Zhou

Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.

Antivir Ther 2017; 22: 237–246.

36.

Sun

J.H.

, O'Boyle

D.R.

2nd , Zhang

Impact of a baseline polymorphism on the emergence of resistance to the HCV NS5A replication complex inhibitor BMS-790052.

Hepatology 2012; 55: 1692–1699.

37.

McPhee

, Falk

, Lemm

Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin.

J Hepatol 2012; 56 Suppl 2: S473.

38.

Ikeda

, Saitoh

, Kobayashi

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data.

Hepatol Res 2000; 18: 252–266.

39.

Clopper

, Pearson

E.S.

The use of confidence or fiducial limits illustrated in the case of the binomial.

Biometrika 1934; 26: 404–413.

40.

Safadi

, Noviello

, Boparai

, McPhee

Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir.

Clin Case Rep 2016; 4: 653–656.